FDA Approves Zanvastro, First Disease-Modifying Treatment for Alexander Disease

The U.S. Food and Drug Administration (FDA) has approved Zanvastro (zilganersen) injection, making it the first disease-modifying treatment for Alexander disease in both pediatric and adult patients. This RNA-targeted antisense therapy directly addresses the underlying protein buildup that drives this ultra-rare, progressive neurological disorder.